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Abstract: Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m
2, paclitaxel 155 mg/m
2 
(both day 1) and capecitabine 665 mg/m
2 twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduc-
tion. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression 
and overall survival were 6.6 and 23.5 months, respectively.
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Introduction
The majority of patients with metastatic breast cancer (MBC) receive front-line chemotherapy. 
Anthracycline- and taxane-containing regimens are among the most active in MBC that is rapidly 
progressing or unresponsive to hormonal therapy (Biganzoli et al. 2002; Jassem et al. 2001; Nabholtz 
et al. 2003; Bonneterre et al. 2004; Sledge et al. 2003). Capecitabine demonstrates consistently high 
single-agent activity in pretreated MBC (Blum et al. 1999; Blum et al. 2001; Fumoleau et al. 2004; 
Reichardt et al. 2003) and is a promising ﬁ  rst-line therapy (O’Shaughnessy et al. 2001; Stockler et al. 
2007). In a randomized, phase III trial, ﬁ  rst-line capecitabine signiﬁ  cantly improved overall survival 
compared with ‘classical’ cyclophosphamide, methotrexate and 5-ﬂ  uorouracil (CMF) (Stockler et al. 
2007). Capecitabine has a favorable tolerability proﬁ  le (Blum et al. 1999; Blum et al. 2001; Fumoleau 
et al. 2004; Reichardt et al. 2003; O’Shaughnessy et al. 2001; Stockler et al. 2007), including minimal 
myelosuppression, making it an appealing combination partner for other cytotoxics. Furthermore, 
capecitabine shows preclinical synergy with taxanes (Sawada et al. 1998). This observation has been 
substantiated by ﬁ  ndings from a large, randomized clinical trial, which showed that capecitabine plus 
docetaxel signiﬁ  cantly improved overall survival, time to disease progression and response rate compared 
with docetaxel alone in anthracycline-pretreated MBC (O’Shaughnessy et al. 2002). The combination 
of capecitabine and paclitaxel has demonstrated promising activity in phase II and III studies (Batista 
et al. 2004; Gradishar et al. 2004; Blum et al. 2006; Soto et al. 2006; Lück et al. 2007).
As current evidence suggests that three of the most active cytotoxic agents in MBC are the 
anthracyclines, taxanes and capecitabine, there is a rationale for studying the triplet combination of 
paclitaxel, epirubicin and capecitabine (TEX).
Patients and Methods
This non-comparative, open-label study was designed to determine the optimal doses of each component 
drug and evaluate the safety and feasibility of TEX as ﬁ  rst-line treatment for MBC. The study was 
conducted with ethics committee approval.
Patient selection
Women 18 years old with documented MBC who had not received previous chemotherapy for 
MBC were eligible. Previous adjuvant chemotherapy was permitted if completed at least 12 months 534
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before relapse. Patients were to have at least 
one measurable lesion (at least one dimen-
sion 20 mm or 10 mm by conventional 
or spiral computed tomography [CT] scan, 
respectively); Eastern Cooperative Oncology 
Group (ECOG) performance score of 0–2; 
white blood cell (WBC) count 3.0 × 10
9/l; 
platelet count 100 × 10
9/l; serum creati-
nine 1.25 × upper normal limit (UNL); total 
bilirubin 1.25 × UNL; normal cardiac function; 
and a life expectancy of 3 months. All patients 
provided written informed consent.
Exclusion criteria included a history of neo-
plasm other than breast carcinoma, except for 
non-melanoma skin cancer or curatively treated 
carcinoma in situ of the cervix; pregnancy or 
lactation; known brain metastases; a history of 
cardiac arrhythmias and/or congestive heart 
failure or myocardial infarction; pre-existing 
motor or sensory neuropathy; severe hepatic 
impairment; severe renal impairment (creatinine 
clearance 30 ml/min); history of dihydropy-
rimidine dehydrogenase (DPD) deﬁ  ciency; active 
infection; or other serious underlying medical 
condition.
Drug administration
Study treatment consisted of combination therapy 
with paclitaxel, epirubicin and capecitabine. 
Epirubicin was given as a 30-min intravenous 
infusion on day 1 followed 30 min later by a 3-h 
intravenous infusion of paclitaxel; capecitabine was 
given orally twice daily for 14 days. Treatment 
was repeated every 3 weeks and continued until 
disease progression or unacceptable toxicity, or 
for as long as deemed appropriate by the inves-
tigator. All patients received premedication 
consisting of cetirizine 10 mg orally, 20 mg 
intravenous betamethasone. and 50 mg intrave-
nous ranitidine.
Dose adjustments
Starting doses in all patients were paclitaxel 
155 mg/m
2, epirubicin 60 mg/m
2 and capecitabine 
665 mg/m
2 twice daily (level 0). Doses were esca-
lated and reduced according to the tolerability of 
the treatment in each patient.
In the event of severe toxicity, doses were 
reduced to the preceding dose level according to 
Table 1, or if at dose level 0, at the discretion of 
the treating physician. Dose reductions of one or 
more agents were applied in the event of adverse 
events as follows: grade 3 hematological 
(epirubicin, paclitaxel); grade 2 mucositis 
or cardiac symptoms (epirubicin, capecitabine); 
grade 3 peripheral neuropathy, hypersensitivity 
reaction or arthralgia/myalgia (paclitaxel); 
grade 3 vomiting (epirubicin); grade 2 
hand-foot syndrome or diarrhea (capecitabine). 
For all other treatment-related adverse events of 
grade 2, doses of the suspected drug(s) were 
reduced according to Table 1. Doses were esca-
lated stepwise in the absence of toxicity, and 
maintained at the same dose if patients experi-
enced grade 1 toxicity.
Pretreatment assessment 
and follow-up
At baseline, patient history was recorded and 
cardiac investigations were performed (including 
electrocardiogram, and echocardiography/
multigated radionuclide angiography [MUGA] 
scan if patients had signs or symptoms of cardiac 
disease at study entry). Physical examination, 
ECOG performance status and biochemistry tests 
(serum creatinine, total bilirubin, alkaline 
phosphatase, aspartate aminotransferase) were 
performed at baseline and on day 1 of each 
treatment cycle. Routine laboratory tests 
(hemoglobin, WBC and platelet count) were 
performed at baseline and on day 10, day 12 or 
Table 1. Dose levels for paclitaxel, epirubicin and capecitabine.
Dose level Paclitaxel 
(mg/m
2, d1) 
3-h infusion
Epirubicin 
(mg/m
2, d1) 
30-min infusion
Capecitabine 
(mg/m
2, b.i.d.) 
d1–14 p.o.
0 (starting dose level) 155 60 665
1 175 75 825
2 200 90 1000
b.i.d., twice daily; p.o., orally.535
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13 and day 15 of the ﬁ  rst cycle, and at day 1 and 
the day of nadir for subsequent cycles.
Patients were screened by CT scan and bone 
scan and with magnetic resonance imaging (MRI) 
and bone X-ray if indicated. CT scan or MRI was 
performed at baseline, after every third cycle and 
at termination of study treatment. Patients 
underwent regular follow-up after discontinuing 
treatment until disease progression or death. Tumor 
response was evaluated according to Response 
Evaluation Criteria In Solid Tumors (RECIST) 
(Therasse et al. 2000), except for patients with 
bone metastases only, in whom tumor response 
was evaluated according to World Health 
Organization (WHO) criteria (WHO, 1979). Since 
the study was designed to assess feasibility rather 
than efﬁ  cacy, this variation in response assessment 
was considered necessary and acceptable. 
Response duration was measured according to 
RECIST/WHO criteria (Therasse et al. 2000; 
WHO, 1979).
Toxicities were graded after each treatment 
cycle using National Cancer Institute Common 
Toxicity Criteria (NCI-CTC), version 2.0.
Results
Patient characteristics and treatment 
exposure
Thirteen patients were enrolled from 3 centers 
(Table 2). A total of 100 cycles of TEX were given 
(median 6 per patient, range 1–15). Reasons for 
discontinuing therapy were toxicity (n = 4), disease 
progression (n = 2), patient request (n = 5; 4 of 
whom were told at the start of treatment that they 
could elect to switch to ‘standard’ treatment after 
6 cycles), complete remission (n = 1), or death from 
disease progression (n = 1). The patient with 
complete remission achieved this response after 
3 cycles. The patient was switched to endocrine 
therapy after 4 cycles based on modest toxicity and 
the complete tumor response.
Dose escalation was implemented in 
10 patients, with epirubicin and capecitabine 
being most frequently escalated by one dose step. 
Figure 1 shows the number of cycles given at 
each dose level for each agent. Treatment with 
capecitabine alone or in combination with either 
paclitaxel or epirubicin was continued in 
4 patients following termination of the triplet 
combination. The most commonly administered 
dose level for each drug was level 0, and therefore 
this dose level is recommended for further 
evaluation.
Safety
The majority (86%) of adverse events were grade 
1 or 2. The most commonly reported adverse events 
were fatigue, nausea, neuropathy and myalgia/
arthralgia (Fig. 2). Grade 3/4 events were mucositis, 
diarrhea, infection, neuropathy and myalgia/
arthralgia. Mean changes in WBC count are 
presented in Table 3. Seven patients experienced 
a total of 14 episodes of grade 3 (11 episodes) or 
4 (3 episodes) leukopenia (5 patients experienced 
at least one grade 3 episode and 2 patients experi-
enced at least one grade 4 episode). In all but one 
case, grade 3/4 leukopenia occurred at dose levels 
above level 0.
Table 2. Baseline patient characteristics (n = 13).
Characteristic
Median age, years (range) 50 (43–65)
ECOG performance status, n (%)
 0 5  (38%)
 1 8  (62%)
Hormone receptor status, n (%)
  ER and/or PgR positive 10 (77%)
  ER and PgR negative 2 (15%)
 Unknown 1  (8%)
Histology, n (%)
 Ductal 12  (92%)
 Lobular 1  (8%)
Median no. of metastatic sites (range) 2 (1–3)
Metastatic sites, n (%)
 Bone 7  (54%)
 Liver 5  (38%)
 Lung 3  (23%)
Previous therapy, n (%)
 Radiotherapy 11  (85%)
 Hormonal  therapy 8
a (62%)
 Adjuvant  chemotherapy 5
b (38%)
aAdjuvant therapy (n = 2); ﬁ  rst-line therapy (n = 6).
bTailored 5-ﬂ  uorouracil, epirubicin and cyclophosphamide (n = 2), 
cyclophosphamide, methotrexate and 5-ﬂ  uorouracil (n = 2) and 
doxorubicin and docetaxel (n = 1).
ECOG, eastern cooperative oncology group; ER, estrogen receptor; 
PgR, progesterone receptor.536
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No patients required granulocyte colony 
stimulating factor support and none experienced 
cardiotoxicity, despite prior adjuvant anthracycline 
therapy in 3 patients.
Efﬁ  cacy
Nine patients achieved an objective response, 
including complete remission in a patient who 
received 4 cycles of TEX (paclitaxel and epirubicin 
at dose level 0, capecitabine at dose level 1). Two 
patients had stable disease. One showed disease 
progression, and 1 was not evaluable due to early 
toxicity. Median time to treatment failure was 
4.9 months (range 0.4–11.8). At 19 months’ median 
follow-up, the median time to tumor progression 
and median overall survival were 6.6 (range 
2.2–15.5) and 23.5 (range 7.3–65+) months, 
respectively.
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Figure 1. Proportion of cycles administered by drug and dose level.
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Figure 2. Non-hematological adverse events reported with paclitaxel, epirubicin and capecitabine (TEX) combination therapy.537
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Discussion
In this pilot, phase I/II feasibility study, a regimen 
of paclitaxel 155 mg/m
2, epirubicin 60 mg/m
2 and 
capecitabine 665 mg/m
2 twice daily was identiﬁ  ed 
as a feasible, tolerable and active ﬁ  rst-line treat-
ment for MBC. Consistent with the known toxici-
ties of each agent, the most frequent adverse events 
were fatigue, nausea, sensory neuropathy and 
myalgia/arthralgia. Most events were mild or mod-
erate in intensity, with grade 3/4 toxicities compris-
ing only 14% of reported events. In contrast to an 
early study of docetaxel-epirubicin-capecitabine 
(Venturini et al. 2003), myelosuppression was 
manageable in this study, probably due to the lower 
anthracycline and taxane doses. Only 7 patients 
experienced grade 3/4 leukopenia and none expe-
rienced febrile neutropenia, although infection was 
reported in a patient receiving the majority of 
courses of capecitabine at dose level 0 and pacli-
taxel and epirubicin at dose level 2.
Although this very small study was not designed 
to determine efficacy, we observed objective 
responses in 9 patients (69%). This is similar to 
the 67% response rate reported in a phase II study 
evaluating docetaxel-epirubicin-capecitabine in 
33 women with MBC (Venturini et al. 2003). 
Recently reported results of a randomized, phase III 
trial comparing docetaxel-epirubicin-capecitabine 
with docetaxel-epirubicin showed response rates 
among patients with stage IV disease of 67% and 
53%, respectively (Mansutti et al. 2008). Overall, 
our results are in accordance with those reported 
from other trials (Venturini et al. 2003; Mansutti 
et al. 2008), although the very small number of 
patients in our study means that such comparisons 
should be treated with caution. In addition, it is 
important to note that in our trial the capecitabine 
dose was considerably lower than the 1000 mg/m
2 
twice daily dose used in phase II and III trials 
evaluating docetaxel-epirubicin-capecitabine.
Currently, the most commonly used 
chemotherapeutic agents for the treatment of 
breast cancer are anthracyclines and taxanes. 
Capecitabine is highly active and may further 
improve outcomes, possibly through synergy 
between capecitabine and taxanes and with 
the benefit of non-overlapping toxicity. In 
chemo-naïve patients with good performance 
status, the primary aim is to achieve disease and 
symptom control. Consequently, TEX is being 
compared with paclitaxel-epirubicin as ﬁ  rst-
line therapy for MBC in an ongoing Swedish 
phase III trial.
Increasingly, drugs with deﬁ  ned targets (such 
as bevacizumab in combination with a taxane 
(Miller et al. 2007; Miles et al. 2008)) are becom-
ing an important part of breast cancer treatment. 
With further study, it should become clear how 
these agents should be integrated into standard 
ﬁ  rst-line therapy for MBC.
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